Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

Abstract The European LeukemiaNet recently revised both the clinical (2022) and
measurable residual disease testing (2021) guidelines for acute myeloid leukemia (AML) …

Outcome in patients with acute myeloid leukemia (AML) ranges from death within a few days
of beginning treatment (treatment related mortality, TRM) to likely cure. The major reason …

Abstract Purpose of Review Awareness of the molecular landscape of AML has improved
AML care over the last 5 years. This review summarizes updates regarding the diagnostic …

Abstract With the Food and Drug Administration approval of 9 agents for different acute
myeloid leukemia (AML) indications, the prognosis and management of AML is evolving …

Acute myeloid leukemia (AML) is a malignancy of the stem cell precursors of the myeloid
lineage (red blood cells, platelets, and white blood cells other than B and T cells). Like other …

Management of AML involves choosing between purely palliative care, standard therapy
and investigational therapy (“clinical trial”). Even most older patients likely benefit from …

Acute myeloid leukemia (AML) is a malignant disorder of the bone marrow which is
characterized by the clonal expansion and differentiation arrest of myeloid progenitor cells …

Current treatment of acute myeloid leukemia : Current Opinion in Oncology Current treatment of
acute myeloid leukemia : Current Opinion in Oncology Log in or Register Subscribe to …

Disease overview Acute myeloid leukemia (AML) results from accumulation of abnormal
blasts in the marrow. These cells interfere with normal hematopoiesis, can escape into the …